← Back to Clinical Trials
Recruiting NCT06701955

NCT06701955 Study of the Test-retest Reliability of the Neuropsychiatric Fluctuations Scale in Parkinson's Disease

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06701955
Status Recruiting
Phase
Sponsor University Hospital, Grenoble
Condition Parkinson's Disease
Study Type INTERVENTIONAL
Enrollment 100 participants
Start Date 2025-02-01
Primary Completion 2026-11-01

Eligibility & Interventions

Sex All sexes
Min Age 30 Years
Max Age 75 Years
Study Type INTERVENTIONAL
Interventions
Questionnaire and Physical Exam

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 100 participants in total. It began in 2025-02-01 with a primary completion date of 2026-11-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study focuses on neuropsychiatric fluctuations (NPF) in Parkinson's disease. Due to the lack of specific assessment tools, we developed the Neuropsychological Fluctuations Scale (NFS), a 20-item questionnaire. Recent studies have confirmed its reliability, sensitivity, and validity. To finalize its validation, assessing its test-retest reliability is an essential next step.

Eligibility Criteria

Inclusion Criteria: Age \> 30 and ≤ 75 years * Idiopathic Parkinson's disease (according to the criteria of the Movement Disorders Society) * Presence of motor fluctuations described by the patient, their relatives, or identified by the clinician * Stability of antiparkinsonian treatment for at least one month * Mastery of the French language * Able to give consent. * Affiliated to the social security system Exclusion Criteria: Parkinsonian syndrome other than idiopathic Parkinson's disease * Dementia (MoCa \< 23) * No antiparkinsonian treatment or treatment modified for less than one month * Persons referred to in Articles L1121-5 to L1121-8 of the CSP (corresponds to all protected persons: pregnant women, parturients, breastfeeding mothers, persons deprived of liberty by judicial or administrative decision, persons receiving psychiatric care under Articles L. 3212-1 and L. 3213-1 who are not covered by the provisions of Article L. 1121-8, persons admitted to a health or social establishment for purposes other than research, minors, persons subject to a legal protection measure or unable to express their consent)) * Subject in a period of exclusion from another interventional study.

Contact & Investigator

Central Contact

Emmanuelle Schmitt, PHD

✉ eschmitt@chu-grenoble.fr

📞 +33 4 76765791

Frequently Asked Questions

Who can join the NCT06701955 clinical trial?

This trial is open to participants of all sexes, aged 30 Years or older, up to 75 Years, studying Parkinson&#39;s Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06701955 currently recruiting?

Yes, NCT06701955 is actively recruiting participants. Contact the research team at eschmitt@chu-grenoble.fr for enrollment information.

Where is the NCT06701955 trial being conducted?

This trial is being conducted at Grenoble, France.

Who is sponsoring the NCT06701955 clinical trial?

NCT06701955 is sponsored by University Hospital, Grenoble. The trial plans to enroll 100 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology